EGFL7 and systemic sclerosis: The expression levels of EGFL7 and miR‐126 significantly increased from 0.20 ± 0.05 folds for EGFL7 and 0.18 ± 0.04 for miR‐126 in SSc‐MVEC untreated control to 0.92 ± 0.15 folds for EGFL7 and 0.97 ± 0.16 for miR‐126 in Aza‐ and TSA‐treated SSc‐MVECs (Figure 6B; P < 0.01), while no effects on EGFL7 and miR‐126 expression levels were noted in NL‐MVECs after treatment with Aza and TSA (Figure 6B).